Announcements
- Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
- Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
- Axogen, Inc Reports First Quarter 2024 Financial Results
- Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
More ▼
Key statistics
As of last trade AxoGen Inc (LT3:FRA) traded at 6.95, -28.72% below its 52-week high of 9.75, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.95 |
---|---|
High | 6.95 |
Low | 6.95 |
Bid | 6.95 |
Offer | 7.25 |
Previous close | 6.85 |
Average volume | 0.00 |
---|---|
Shares outstanding | 43.70m |
Free float | 39.88m |
P/E (TTM) | -- |
Market cap | 334.78m USD |
EPS (TTM) | -0.4943 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 07:04 BST.
More ▼